HealthInvestor’s Post

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline https://lnkd.in/dSp5hqXn #pharmaindustry #pharmanews #funding Adcendo TCGX TPG OrbiMed Venrock Surveyor Capital RA Capital Management Novo Holdings Pontifax Venture Capital Dawn Biopharma KKR HealthCap Gilde Healthcare Ysios Capital Michael Pehl Cariad Chester John Haurum Nandita Shangari Jeroen Bakker Carolyn Ng ohad hammer Iyona Rajkomar, MBBS, CFA Roy Amariglio

➖ CAPITAL RAISE ➖   Adherium has announced a $8.37 million capital raising via a Placement and Non-Renounceable Entitlement Offer.    The Company has received firm commitments for a capital raising of up to $1.57 million before costs, by way of a placement of new shares to sophisticated and professional investors. The placement will be undertaken in two tranches with the second tranche including CEO and Director participation.    Adherium also proposes to undertake a fully underwritten non-renounceable entitlement offer of new shares and new options to eligible shareholders to raise up to $6.8 million before costs.    These funds will be used to fast track US commercialisation of Adherium’s Hailie® Smartinhaler® technology – with multiple FDA clearances and US reimbursement codes now in place.    Adherium CEO, Dr. Paul Mastoridis, said:     “Adherium is entering a defining phase in its commercial development. We are extending the reach and impact of our world-class respiratory health product portfolio within the US, the largest healthcare market in the world. Our Company has a clear and focused US engagement and market penetration strategy, which prioritises manufacturing activities and sales via established pharmaceutical and payor groups in this market.”    For more information, read the ASX release 👉 https://lnkd.in/gs-8BXZX      $ADR #ADR #Adherium #digitalhealth #ehealth #innovation #invest #capitalraise 

The right to health is a basic human right 🏥 On #WorldHealthDay, Amolyt Pharma, with backing from Sofinnova Partners, offers hope to patients worldwide suffering from rare endocrine and related diseases. 💫 €212m raised from VCs 💫 Expansion to 50 employees 💫 $1.05bn acquisition agreement with AstraZeneca With support from investors: Intermediate Capital Group (ICG), Tekla Capital Management, CTI Life Sciences Fund, Andera Partners, Novo Ventures, Kurma Partners, EQT Life Sciences, @Innobio 2 (Bpifrance Investissement), Sectoral Asset Management, Pontifax Venture Capital, OrbiMed, Mass General Brigham Ventures, ATEM, Crédit Agricole Création and Relyens Innovation Santé / Turenne Groupe. Read the full story, and take a look at how investment supports Europe’s most innovative healthcare and life sciences businesses ➡️ https://lnkd.in/emQzXubz #PrivateEquity #VentureCapital #SuccessStories #BuildingBetterBusinesses #pharma #healthcare

Gilde Healthcare company FIRE1 completes $120m financing round led by new investors Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and existing investors Gilde Healthcare, Andera Partners, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, NEA (New Enterprise Associates), Novo Holdings, and Seventure Partners https://lnkd.in/eS93dM98 Gilde Healthcare Polaris Partners Elevage Medical Technologies Sands Capital Longitude Capital Andera Partners Gimv Ireland Strategic Investment Fund Lightstone Ventures Medtronic New Enterprise Associates (NEA) Novo Holdings Seventure Partners More European life science business news at [LSE] Life-Sciences-Europe.com __

France: Case Study - Amolyt Pharma, a portfolio company of Sofinnova Partners sold to AstraZeneca for $1.05bn. Amolyt Pharma represents a major European VC success story – a French company created and incubated by a pioneering entrepreneur, backed by top European investors, including Sofinnova Partners, who led the company’s €130M series C in 2023, with participation from Intermediate Capital Group (ICG) Tekla Capital Investment LLC, CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital. READ the Invest Europe case study here https://lnkd.in/emQzXubz READ the Investors in Healthcare article here https://lnkd.in/ex8GPi53 #lifesciences #venturecapital #healthcare Antoine Papiernik Nicholas Moore Julian Hudson

As the #UNGA meets to discuss anti-microbial resistance, Tenmile has made an investment in Lumos Diagnostics, furthering our commitment to support commercial efforts to stem the threat of #AMR. How does Lumos play a role in this fight? About a month ago, there was a case of whooping cough (caused by Bordetella pertussis, a bacterial infection) in my daughter's pre-school. A week later my daughter started coughing and we promptly visited our GP. While the GP felt it was unlikely to be bacterial, the definitive test would take 2-3 days and so to be safe, recommended #antibiotics. As a parent, it's hard not to take this advice and promptly started antibiotic treatment. Three days later we got the news that it was not a bacterial infection. There was no need for antibiotics, yet we've already exposed our daughters microbiome out of caution, becoming a part of a scary statistic. Approximately 30% of antibiotics are prescribed when they aren't necessary. This is where FebriDx steps in. Lumos has developed FebriDx as a point-of-care diagnostic to distinguish bacterial from non-bacterial infections. In 10 minutes, a GP could have identified that my daughter's cough was not caused by a bacterial infection and that antibiotics would not help. Along with novel antibiotics (Revagenix, Inc.) and vaccines (LimmaTech Biologics AG), #diagnostics will play a key role in identifying bacterial infections, avoiding over-prescription and reducing the burden of AMR.

France’s early-stage medtech sector shows promise, but it will need heavy private equity (PE) investment to reach its potential. French politicians were fiercely opposed to PE firm Clayton Dubilier & Rice‘s (CD&R) plans to invest in Sanofi’s consumer health business Opella, the main producer of over-the-counter drugs like paracetamol. But they don’t show the same passion when it comes to supporting smaller medtech firms and keeping them at home: https://lnkd.in/eRsU2Zag

The fourth edition of Mergermarket's France Deals Pulse looks at a very interesting French conundrum. "Many French politicians were fiercely opposed to PE firm Clayton, Dubilier & Rice (CD&R) plans to invest in Sanofi’s [EPA:SAN] consumer health business Opella, the main producer of over-the-counter drugs like paracetamol. But they don’t show the same passion when it comes to supporting smaller medtech firms and keeping them home." Read more for free here : https://lnkd.in/eFTSwdgx Our previous edition on Sanofi's Opella is still in free access here: https://lnkd.in/e8Fj8JCa